PI3 and Eczematoid dermatitis: Whilst elafin has previously been noted as a potential biomarker of psoriatic inflammation, this study is the first to demonstrate its significant efficacy in distinguishing psoriasis from eczema in ‘real‐world’ epidermal samples.